Wow!
It matters not to PER
Why?
1) Boys that can access the gene therapy drug will get it
others will use other therapies..
2)The cost $3.2 million will be a stumbling block
3) US clinicians are skeptical re efficacy
4)Sarepta is yet to make a profit from the other exon skipping drug
5)Gene therapy has still got a long way to go before it’s widely accepted
6) All in all PER will continue with its path forward
Other exon skipping drugs will use combination therapies.. eg Atl1102
.
https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
